Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation fo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hepatol Commun
Main Authors: Kruger, Annie J., Fuchs, Bryan C., Masia, Ricard, Holmes, Jacinta A., Salloum, Shadi, Sojoodi, Mozhdeh, Ferreira, Diego S., Rutledge, Stephanie M., Caravan, Peter, Alatrakchi, Nadia, Vig, Pam, Lefebvre, Eric, Chung, Raymond T.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944590/
https://ncbi.nlm.nih.gov/pubmed/29761169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1160
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares